Patterns of change in cognitive function with anastrozole therapy

Catherine M. Bender, John Merriman, Amanda L. Gentry, Gretchen M. Ahrendt, Sarah L. Berga, Adam M. Brufsky, Frances E. Casillo, Meredith M. Dailey, Kirk I. Erickson, Frances M. Kratofil, Priscilla F. McAuliffe, Margaret Q. Rosenzweig, Christopher M. Ryan, Susan M. Sereika

Research output: Contribution to journalArticle

Abstract

BACKGROUND The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer. METHODS This large, longitudinal cohort study was composed of postmenopausal women with early-stage breast cancer who received chemotherapy plus anastrozole (n=114) or anastrozole alone (n=173) and a control group (n=110). Cognitive function was assessed before systemic therapy and 6, 12, and 18 months after therapy initiation and at comparable time points in controls. RESULTS The chemotherapy-anastrozole and anastrozole-alone groups had poorer executive function than the controls at nearly all time points (P<.0001 to P=.09). A pattern of deterioration in working memory and concentration was observed during the first 6 months of anastrozole therapy for the chemotherapy-anastrozole group (P<.0001 and P<.0009, respectively) and the anastrozole-alone group (P=.0008 and P=.0002, respectively). This was followed by improved working memory and concentration from 6 to 12 months in both groups. The anastrozole-alone group had a second decline in working memory and concentration from 12 to 18 months after the initiation of therapy (P<.0001 and P=.02, respectively). CONCLUSIONS Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy. A pattern of decline in working memory and concentration with initial exposure to anastrozole was observed. Women receiving anastrozole alone had a second deterioration in working memory and concentration from 12 to 18 months after therapy initiation. The longer term effects (>18 months) of anastrozole on cognitive function remain to be determined. Cancer 2015;121:2627-2636.

Original languageEnglish (US)
Pages (from-to)2627-2636
Number of pages10
JournalCancer
Volume121
Issue number15
DOIs
StatePublished - Aug 1 2015

Fingerprint

Cognition
Executive Function
Therapeutics
Breast Neoplasms
Drug Therapy
Longitudinal Studies
anastrozole
Cohort Studies
Control Groups
Neoplasms

Keywords

  • anastrozole
  • breast cancer
  • chemotherapy
  • cognitive function
  • endocrine therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bender, C. M., Merriman, J., Gentry, A. L., Ahrendt, G. M., Berga, S. L., Brufsky, A. M., ... Sereika, S. M. (2015). Patterns of change in cognitive function with anastrozole therapy. Cancer, 121(15), 2627-2636. https://doi.org/10.1002/cncr.29393

Patterns of change in cognitive function with anastrozole therapy. / Bender, Catherine M.; Merriman, John; Gentry, Amanda L.; Ahrendt, Gretchen M.; Berga, Sarah L.; Brufsky, Adam M.; Casillo, Frances E.; Dailey, Meredith M.; Erickson, Kirk I.; Kratofil, Frances M.; McAuliffe, Priscilla F.; Rosenzweig, Margaret Q.; Ryan, Christopher M.; Sereika, Susan M.

In: Cancer, Vol. 121, No. 15, 01.08.2015, p. 2627-2636.

Research output: Contribution to journalArticle

Bender, CM, Merriman, J, Gentry, AL, Ahrendt, GM, Berga, SL, Brufsky, AM, Casillo, FE, Dailey, MM, Erickson, KI, Kratofil, FM, McAuliffe, PF, Rosenzweig, MQ, Ryan, CM & Sereika, SM 2015, 'Patterns of change in cognitive function with anastrozole therapy', Cancer, vol. 121, no. 15, pp. 2627-2636. https://doi.org/10.1002/cncr.29393
Bender CM, Merriman J, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015 Aug 1;121(15):2627-2636. https://doi.org/10.1002/cncr.29393
Bender, Catherine M. ; Merriman, John ; Gentry, Amanda L. ; Ahrendt, Gretchen M. ; Berga, Sarah L. ; Brufsky, Adam M. ; Casillo, Frances E. ; Dailey, Meredith M. ; Erickson, Kirk I. ; Kratofil, Frances M. ; McAuliffe, Priscilla F. ; Rosenzweig, Margaret Q. ; Ryan, Christopher M. ; Sereika, Susan M. / Patterns of change in cognitive function with anastrozole therapy. In: Cancer. 2015 ; Vol. 121, No. 15. pp. 2627-2636.
@article{b274884fb57c40d0a30b728427aa66e0,
title = "Patterns of change in cognitive function with anastrozole therapy",
abstract = "BACKGROUND The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer. METHODS This large, longitudinal cohort study was composed of postmenopausal women with early-stage breast cancer who received chemotherapy plus anastrozole (n=114) or anastrozole alone (n=173) and a control group (n=110). Cognitive function was assessed before systemic therapy and 6, 12, and 18 months after therapy initiation and at comparable time points in controls. RESULTS The chemotherapy-anastrozole and anastrozole-alone groups had poorer executive function than the controls at nearly all time points (P<.0001 to P=.09). A pattern of deterioration in working memory and concentration was observed during the first 6 months of anastrozole therapy for the chemotherapy-anastrozole group (P<.0001 and P<.0009, respectively) and the anastrozole-alone group (P=.0008 and P=.0002, respectively). This was followed by improved working memory and concentration from 6 to 12 months in both groups. The anastrozole-alone group had a second decline in working memory and concentration from 12 to 18 months after the initiation of therapy (P<.0001 and P=.02, respectively). CONCLUSIONS Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy. A pattern of decline in working memory and concentration with initial exposure to anastrozole was observed. Women receiving anastrozole alone had a second deterioration in working memory and concentration from 12 to 18 months after therapy initiation. The longer term effects (>18 months) of anastrozole on cognitive function remain to be determined. Cancer 2015;121:2627-2636.",
keywords = "anastrozole, breast cancer, chemotherapy, cognitive function, endocrine therapy",
author = "Bender, {Catherine M.} and John Merriman and Gentry, {Amanda L.} and Ahrendt, {Gretchen M.} and Berga, {Sarah L.} and Brufsky, {Adam M.} and Casillo, {Frances E.} and Dailey, {Meredith M.} and Erickson, {Kirk I.} and Kratofil, {Frances M.} and McAuliffe, {Priscilla F.} and Rosenzweig, {Margaret Q.} and Ryan, {Christopher M.} and Sereika, {Susan M.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/cncr.29393",
language = "English (US)",
volume = "121",
pages = "2627--2636",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - Patterns of change in cognitive function with anastrozole therapy

AU - Bender, Catherine M.

AU - Merriman, John

AU - Gentry, Amanda L.

AU - Ahrendt, Gretchen M.

AU - Berga, Sarah L.

AU - Brufsky, Adam M.

AU - Casillo, Frances E.

AU - Dailey, Meredith M.

AU - Erickson, Kirk I.

AU - Kratofil, Frances M.

AU - McAuliffe, Priscilla F.

AU - Rosenzweig, Margaret Q.

AU - Ryan, Christopher M.

AU - Sereika, Susan M.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - BACKGROUND The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer. METHODS This large, longitudinal cohort study was composed of postmenopausal women with early-stage breast cancer who received chemotherapy plus anastrozole (n=114) or anastrozole alone (n=173) and a control group (n=110). Cognitive function was assessed before systemic therapy and 6, 12, and 18 months after therapy initiation and at comparable time points in controls. RESULTS The chemotherapy-anastrozole and anastrozole-alone groups had poorer executive function than the controls at nearly all time points (P<.0001 to P=.09). A pattern of deterioration in working memory and concentration was observed during the first 6 months of anastrozole therapy for the chemotherapy-anastrozole group (P<.0001 and P<.0009, respectively) and the anastrozole-alone group (P=.0008 and P=.0002, respectively). This was followed by improved working memory and concentration from 6 to 12 months in both groups. The anastrozole-alone group had a second decline in working memory and concentration from 12 to 18 months after the initiation of therapy (P<.0001 and P=.02, respectively). CONCLUSIONS Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy. A pattern of decline in working memory and concentration with initial exposure to anastrozole was observed. Women receiving anastrozole alone had a second deterioration in working memory and concentration from 12 to 18 months after therapy initiation. The longer term effects (>18 months) of anastrozole on cognitive function remain to be determined. Cancer 2015;121:2627-2636.

AB - BACKGROUND The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer. METHODS This large, longitudinal cohort study was composed of postmenopausal women with early-stage breast cancer who received chemotherapy plus anastrozole (n=114) or anastrozole alone (n=173) and a control group (n=110). Cognitive function was assessed before systemic therapy and 6, 12, and 18 months after therapy initiation and at comparable time points in controls. RESULTS The chemotherapy-anastrozole and anastrozole-alone groups had poorer executive function than the controls at nearly all time points (P<.0001 to P=.09). A pattern of deterioration in working memory and concentration was observed during the first 6 months of anastrozole therapy for the chemotherapy-anastrozole group (P<.0001 and P<.0009, respectively) and the anastrozole-alone group (P=.0008 and P=.0002, respectively). This was followed by improved working memory and concentration from 6 to 12 months in both groups. The anastrozole-alone group had a second decline in working memory and concentration from 12 to 18 months after the initiation of therapy (P<.0001 and P=.02, respectively). CONCLUSIONS Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy. A pattern of decline in working memory and concentration with initial exposure to anastrozole was observed. Women receiving anastrozole alone had a second deterioration in working memory and concentration from 12 to 18 months after therapy initiation. The longer term effects (>18 months) of anastrozole on cognitive function remain to be determined. Cancer 2015;121:2627-2636.

KW - anastrozole

KW - breast cancer

KW - chemotherapy

KW - cognitive function

KW - endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=84937520484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937520484&partnerID=8YFLogxK

U2 - 10.1002/cncr.29393

DO - 10.1002/cncr.29393

M3 - Article

VL - 121

SP - 2627

EP - 2636

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 15

ER -